Abstract: The present invention relates to a transdermal therapeutic system for cutaneous administration of fampridine. The system includes an active ingredient-impermeable backing layer, a pressure-sensitive adhesive reservoir layer and optionally a detachable protective layer. The pressure-sensitive adhesive reservoir layer is formed from fampridine and at least one matrix polymer containing no free carboxylic acid and/or carboxylate groups, with the content of fampridine in the matrix polymer being <5% by weight. On account of the low loading and also the lack of carboxylic acid and/or carboxylate groups in the reservoir layer, it is ensured that the systems administer the active ingredient substantially at higher administration rates than is known in the prior art, and compared to known systems a comparable thermodynamic activity of the active ingredient is achieved. The present invention further relates to a process for producing corresponding transdermal therapeutic systems.

Abstract: The present invention relates to the use of cannabidiol (CBD) in combination with an agonist of 5-HT2B receptors. Such a combination provides protection against the adverse effects caused by agonists of 5-HT2B receptors. The invention further relates to the use of CBD in combination5 with an amphetamine or amphetamine derivative in the treatment of epilepsy. In one embodiment the CBD is used in combination with the amphetamine derivative fenfluramine to produce a significant reduction in seizures. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid10 tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

Abstract: Formulations comprising complexes of peptides with hydrophobic bioactive molecules are described herein. The invention more specifically relates to collagen peptide and curcuminoid complexes and compositions comprising the complexes. The compositions and formulations comprising the protein hydrolysate peptide-hydrophobic bioactive molecule complexes are water-soluble, stable at physiological and acidic pH, synergistically enhance the systemic bioavailability of the biomolecules and peptides, and are capable of delivering a high therapeutically effective amount of the bioactive molecules via oral route. The compositions and formulations comprising the collagen peptide-curcuminoid complexes provide significantly high levels of bioavailable curcuminoids that are water soluble and stable at physiological and acidic pH along with significant anti-inflammatory effects offered by collagen peptides.

Abstract: The present invention relates to specific ?-hydroxyketones of the formula (I) for use in the prevention and/or treatment of photodermatoses and to the use of specific ?-hydroxyketones of the formula (I) as active ingredient in typical compositions for the prevention and/or non-therapeutic treatment of photodermatoses, in particular of polymorphic light eruption.

Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.

Abstract: The present invention is directed to 13C and/or 2H isotope enhanced ambroxol (“isotope enhanced ambroxol”) and its use in the treatment of autophagy infections, especially mycobacterial and other infections, disease states and/or conditions of the lung, such as tuberculosis, especially including drug resistant and multiple drag resistant tuberculosis. Pharmaceutical compositions comprising isotope enhanced ambroxol, alone or in combination with an additional bioactive agent, especially rifamycin antibiotics, including an additional autophagy modulator (an agent which is active to promote or inhibit autophagy), thus being useful against, an autophagy mediated disease state and/or condition), especially an antophagy mediated disease state and/or condition which occurs in the lungs, for example, a Mycobacterium infection.

Abstract: The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.

Abstract: The present disclosure relates to nanoemulsion compositions with certain surfactant blend ratios that impart enhanced permeability. Such compositions are useful for mucosal and intranasal applications and allow for the greater delivery of one or more active agents to the application site to prevent infection by coronavirus.

Abstract: A solid pharmaceutical composition suitable for oral administration, comprising: (a) S 1 P receptor agonist; and (b) a sugar alcohol.

Abstract: A method for increasing susceptibility of microorganisms to antibiotics includes providing a microorganism; administering an antibiotic including a nitro-containing amphenicol compound to the microorganism; and administering any of an uronic, aldonic, ulosonic, and aldaric feedstock to the microorganism. The feedstock is adapted to promote cell metabolism, and inhibit antibiotic inactivation pathways in the microorganism causing increased sensitivity of the microorganism to the nitro-containing amphenicol.

Abstract: A method of reducing the virulence of a bacterium that expresses accessory gene regulator A (AgrA) includes administering to the bacterium an amount of AgrA antagonist effective to inhibit the synthesis of one or more virulence factors by the bacterium.

Abstract: The present invention concerns the use of compounds for preventing and/or treating osteoporosis, for stimulating bone formation, for stimulating bone remodeling, for stimulating the differentiation and mineralization of osteoblasts, for inhibiting bone resorption and for modulating serum level of adiponectin in a subject. These uses have been found for compounds represented by Formula I and pharmaceutically acceptable salts thereof, wherein A is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R1 is H, F or OH; R2 is H, F, OH, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R3 is H, F, OH or CH2Ph; R4 is H, F, or OH; Q is 1) (CH2)mC(O)OH wherein m is 1 or 2, 2) CH(F)—C(O)OH, 3) CF2—C(O)OH, or 4) C(O)—C(O)OH.

Abstract: A pharmacological composition for the treatment of bacterial and protozoal infections in a patient. The preferred pharmacological composition comprises a pharmaceutical carrier and an active composition selected from the group consisting of: a) an amount of sodium oxalate and an amount of oxalic acid, b) an amount of sodium citrate and an amount of citric acid, or c) mixtures of a) and b). The amounts and weight ratios of a) the sodium oxalate and oxalic acid, and b) the sodium citrate and citric acid in the active composition are such as to produce a safe and effective pharmacological composition. Sodium salts of other carboxylic acids may be used. The invention also relates to the method of using the pharmacological composition for the safe and effective treatment of bacterial infections, protozoal infections and dermatological diseases.

Abstract: A stable liquid formulation for parenteral administration that includes levothyroxine or a pharmaceutically acceptable salt thereof. The formulation includes a low concentration of an antioxidant, an amino acid as a pH adjuster and a stabilization agent in an aqueous solution that has a pH of about 9 to about 11.5. The parenteral liquid formulation is a stable formulation that is supplied as a ready-to-use or ready-to-administer product in a container or vial.

Abstract: In one aspect, methods of treating non-alcoholic steatohepatitis (NASH) or preventing or delaying the progression of non-alcoholic fatty liver disease (NAFLD) to NASH are provided. In some embodiments, the method comprises administering a therapeutically effective amount of ubenimex.

Abstract: The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of a perillyl alcohol derivative such as a perillyl alcohol ester, or an isoperillyl alcohol derivative such as an isoperillyl alcohol ester. The derivative may be a perillyl alcohol or an isoperillyl alcohol conjugated with a therapeutic agent such as valproic acid. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

Abstract: Methods of treating a viral infection in a subject are provided. The methods include administering a therapeutically effective amount of a pharmaceutical composition comprising ginkgolic acid (GA) to the subject in need thereof, where the virus comprises an enveloped virus. Further provided are specific viral infections that can be treated using the methods.

Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing or preventing membrane cholesterol domain formation in a subject, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing or preventing sdLDL oxidation in a subject, the method comprising administering to the subject a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Abstract: The invention describes pharmaceutical, dietary and/or food compositions, preferably dietary supplements, exerting the ability to activate the endogenous antioxidant system by feeding essential micronutrients to both the one carbon cycle and the trans-sulfuration pathway so to achieve effective oxy-redox homeostasis together with an improved energy balance and healthy processes of cell growth and differentiation including DNA methylation and epigenetic regulation. The invention further relates to the use of the aforementioned compositions to decrease homocysteine levels and for the support to menopause, pregnancy and reproductive competence and for the prevention and/or treatment of diabetes, celiac disease, neurodegenerative diseases, cardiovascular diseases, Autism Spectrum Disorders (ASD) or Neurodevelopmental Disorders.

Abstract: The invention provides compositions comprising chlorogenic acid and methods for their use and manufacture in the treatment of Alzheimer's disease. The compositions can be formulated from botanical sources of chlorogenic acid including sunflower seed extract.

Abstract: Disclosed is the use of oleacein to inhibit foam cell formation process by effective inhibition of oxLDL uptake by macrophages, particularly by reducing expression of macrophage scavenger receptors. Oleacein-comprising pharmaceutical preparations produced according to the invention are viable for use in the treatment and/or prevention of atherosclerosis, particularly in the prevention of early atherosclerotic lesions.

Abstract: The present invention comprises compounds of formula (I): where R1 may be PEG or other polymeric moieties. For example, R1 may be repeating PEG units —(CH2—CH2—O)n—, wherein n=1-455. R1 may also be other polymeric moieties of varying sizes and structures, for example, R1 may be poly(glycolide), poly(lactic acid), poly(lactide), poly(caprolactone), poly(lactide-co-caprolactone), poly(lactide-co-glycolide), or poly(lactic acid)-butanol. One or more embodiments of the invention may also relate to injectable pharmaceutical compositions comprising polymer conjugated monomethyl fumarate, and methods for treating relapsing-remitting multiple sclerosis and psoriasis.

Abstract: This disclosure describes the ability of glycerol monolaurate, formulated both as a solution and as a nonaqueous gel, to kill antimicrobial resistant C. auris. Additionally, this disclosure describes the ability of glycerol monolaurate formulated as a non-aqueous gel to kill clinically isolated Candida species.

Abstract: The present invention relates to purified 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt thereof, and a method for preparing such compound. The compound has at least 90% (w/w) purity. The present invention is also directed to a pharmaceutical composition comprises the purified compound and a pharmaceutically acceptable carrier. The present invention is further directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

Abstract: Provided is a pharmaceutical composition for oral administration, including (a) a taxane, (b) a medium chain triglyceride, (c) an oleoyl glycerol complex having 30 to 65% by weight of monooleoyl glycerol contents; 15 to 50% by weight of dioleoyl glycerol contents; and 2 to 20% by weight of trioleoyl glycerol contents, (d) a surfactant, and optionally (e) polyoxyl glyceryl fatty acid ester and a process for preparing the same.

Abstract: The present invention relates to a method for the treatment of cancer in a cancer patient.

Abstract: Compounds, methods, and compositions are provided for the treatment of cancer, neurological disorders, and fibrotic disorders. Specifically, the invention includes administering an effective amount of a compound of Formula I, II, or III, or a pharmaceutically acceptable composition, salt, isotopic analog, prodrug, or combination thereof, to a subject suffering from a cancer, neurological disorder, or fibrotic disorder.

Abstract: The present invention relates to a pharmaceutical composition comprising vitamin C, or pharmaceutically acceptable salt, solvate or hydrate thereof, in combination with vitamin K1, or pharmaceutically acceptable salt, solvate or hydrate thereof, and may or may not include chromium, or a pharmaceutically acceptable salt, solvate, or hydrate thereof and a pharmaceutically acceptable carrier. Further provided herein is the method of treating, managing, or preventing cancer in human comprising administering a predetermined dosage of pharmaceutical composition comprising Vitamin C or pharmaceutically acceptable salts thereof and Vitamin K1 or a pharmaceutically acceptable salt thereof and may or may not include chromium, or a pharmaceutically acceptable salt, solvate, or hydrate thereof at a predetermined time.

Abstract: The present disclosure provides pharmaceutical compositions, combinations, and uses thereof for treating and/or preventing cancer. For example, a pharmaceutical composition of the present disclosure can also include 2-acetylnaphtho[2,3-b]furan-4,9-dione, a prodrug thereof, a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutically acceptable solvate of any of the foregoing; and at least one excipient independently being a binder, a disintegrant, a lubricant, a surfactant, one other excipient, or a combination thereof. For example, a combination of the present disclosure can include 2-acetylnaphtho[2,3 b]furan-4,9-dione, a prodrug thereof, a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutically acceptable solvate of any of the foregoing; and at least one second agent independently being; a metabolic inhibitor, a transporter inhibitor, a NSAID, or a combination thereof.

Abstract: Embodiments of the invention relate to the treatment of sleep disturbances in individuals with Smith-Magenis Syndrome (SMS).

Abstract: A composition comprising a cannabinoid, in particular a phytocannabinoid or a synthetic cannabinoid, where the cannabinoid is stabilised against oxidation and/or photochemical degradation, characterized in that the composition comprises a micellar solution of composite micelles in an aqueous solution and where the composite micelles encapsulate the cannabinoid.

Abstract: The present application includes a transdermal base formulation useful for example, for the transdermal delivery of active pharmaceutical ingredients along with a process for preparation thereof. In particular, the transdermal base formulation comprises: (a) an aqueous phase comprising water and at least one emulsion stabilizer; (b) an oil phase comprising at least one emulsifier, at least one emulsion stabilizer, at least one emollient comprising at least one flavonoid, at least one other emollient, and a terpene-rich natural butter; (c) an external phase comprising at least one terpene-rich extract or oil, at least one penetration enhancer and a phospholipid-complexed flavonoid; and optionally (d) at least one preservative phase.

Abstract: There is provided a pharmaceutical composition suitable for topical administration to an eye, which contains a selective COX-2 inhibitory drug or salt thereof having a high water solubility and lipophilicity, concomitant with high potency, in a concentration effective for treatment and/or prophylaxis of a disorder in the eye, and one or more ophthalmically acceptable excipients that reduce rate of removal from the eye such that the composition has an effective residence time of about 1 to about 36 hours. Also provided is a method and kit for treating and/or preventing a disease or disorder in an eye, the method comprises administering to the eye a composition of the present disclosure.

Abstract: Methods of treating or preventing allergic or pulmonary diseases characterized by endothelial dysfunction with Alda-1 are presented. Treatment of pulmonary endothelial cells subjected to hyperoxia with Alda-1 showed an increase in ALDH2 activity and expression. Treatment with Alda-1 also illustrated a decrease in oxidative stress, a decrease in reactive oxygen species (ROS), a decrease in apoptosis, a decrease in inflammation and an enhancement of mitochondrial membrane potential.

Abstract: Disclosed are compositions comprising substituted nitrostyrene compounds, as well as methods for their manufacture. Also disclosed are methods of using these compounds in the treatment and/or amelioration of symptoms of bacterial infections such as those caused by Staphylococcus app. (including vancomycin-resistant strains of S. aureus) and Enterococcal spp.

Abstract: Provided is a method for treating a symptom of vibrio infection by using an RTX toxin production inhibitor comprising N-(4-oxo-4H-thieno[3,4-c]chromen-3-yl)-3-phenylprop-2-ynamide having derivatives thereof which can repress (prevent or treat) a symptom of vibrio infection by inhibiting RTX toxin production, other than directly killing vibrio bacteria, to not allow vibrio bacteria to have pathogenicity, and thereby can be an alternative to antibiotics that aim to kill bacteria themselves and thus fundamentally retain the problem of resistance incurrence.

Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.

Abstract: An object he present invention is to provide a medicament for therapy of alcohol use disorder.

Abstract: The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of alcohol use by an alcohol use disorder patient; in preventing relapse into alcohol use by an alcohol use disorder patient; in the promotion of alcohol abstinence by an alcohol use disorder patient; in the treatment of the symptoms of depression or anxiety associated with alcohol use disorder.

Abstract: The invention relates in part to a method of maintaining heavy metal homeostasis in healthy humans, comprising chronically administering to healthy humans a pharmaceutical composition consisting of from about 1 mg to less than about 200 mg of Posiphen or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable excipients, on a once a day basis. By virtue of this method, prophylactic treatment of a potential disease state such as a neurodegenerative disease, cardiovascular homeostasis, cancer, vital organ homeostasis, and the like. The invention also relates in part to a method of restoring heavy metal homeostasis in sick patients, comprising chronically administering to a sick patient a pharmaceutical composition consisting of from about 1 mg to less than about 200 mg of Posiphen or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable excipients, on a once a day basis.

Abstract: The present invention relates to a sodium salt of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1H-pyrazole-3-sulfonamide and to hydrates, solvates and polymorphic forms thereof. The present invention further relates to pharmaceutical compositions comprising this compound and the use of this compound in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.

Abstract: Adrenergic receptor modulating compounds and methods of using the same are provided. Also provided are methods of treating a subject for a disease or condition associated with an adrenergic receptor including administering a therapeutically effective amount of the subject compound. Aspects of the disclosure include a method of modulating an inflammatory pathway in a cell, such as the production of TNF-alpha in the cell. The method can include contacting a cell with ?1-selective adrenergic receptor modulating compound to selectively activate a cAMP pathway over a beta-arrestin pathway in the cell. Pharmaceutical compositions and kits which include the subject compounds are provided.

Abstract: The disclosure provides compounds. In certain embodiments, compounds of the disclosure are capable of inhibiting a mammalian SHMT, such as human SMHT1 and/or SHMT2. Compounds of the disclosure have numerous uses.

Abstract: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.

Abstract: The present invention relates to methods of treating or preventing arthropod infestations of poultry animals and methods of controlling arthropod infestations in poultry animal's environment by administering an isoxazoline compound of formula (I) via drinking water.

Abstract: Disclosed herein are chemotherapeutic methods for the treatment of cancer in humans. In at least one specific embodiment, the method can include administering a therapeutic effective amount of one or more p38 inhibitor compound or salt thereof to a human. The method can also include administering a therapeutic effective of one or more IL-6 inhibitor or one or more IL-6 receptor inhibitor or salt thereof to the human. The method can also include administering a therapeutic effective amount of one or more cytotoxic compound or salt thereof to the human.

Abstract: The present invention concerns the synthesis and use of formulations of 5-substituted 2, 4-thiazolidinediones, pseudothiohydantoins, and propseudothiohydantoins and 2, 4-thiazolidinediones metforminate salts for topical and systemic treatments of infections caused by Herpes simplex viruses and Varicella zoster viruses.

Abstract: The present invention provides a novel dosage principle for compounds of formula I and pharmaceutically acceptable derivatives thereof as defined in the claims, wherein said compound or pharmaceutically acceptable derivative thereof is intravenously administered to said patient over a period of at least about 8 hours, wherein the dose of the compound of formula I or pharmaceutically acceptable derivative thereof is at least the molar equivalent of about 45 mg/m2 of the dihydrochloride salt of the compound of formula I-B as defined in the claims.

Abstract: A pharmaceutical composition comprising cloxacillin for use as a medicament for the prevention of bacterial biofilm formation. Use of cloxacillin for the prevention and/or inhibition of bacterial biofilm formation on a surface.